-
Article
Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
Correction to: Leukemia (2017) 31, 1611–1621; doi:10.1038/leu.2016.352; published online 3 January 2017 Following the publication of this article, it was noted that the HTML version contained the wrong AAP dat...
-
Article
Open AccessA TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
Anti-CD20 monoclonal antibodies (mAb) such as rituximab have been proven to be highly effective at improving outcome in B-cell malignancies. However, many patients ultimately relapse and become refractory to t...
-
Article
Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response
Effective anticancer treatments often result in the induction of large amounts of tumour cell death. In vivo, such dying tumour cells are a potential source of antigens for T-cell stimulation. Although apoptosis ...
